What are the pros and cons of bispecific antibodies for multiple myeloma?
Multiple Myeloma Hub
Comparing CAR-T and Bi-specific Antibodies in Multiple Myeloma Treatment
Exploring the efficacy, patient inclusion, and sequencing considerations of CAR-T therapy versus bi-specific antibodies for multiple myeloma treatment. Discussion includes response longevity, off-the-shelf availability, and infection monitoring challenges of both treatments.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
